GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroBiologics Inc (NAS:FBLG) » Definitions » Debt-to-Equity

FibroBiologics (FibroBiologics) Debt-to-Equity : 1.39 (As of Dec. 2023)


View and export this data going back to 2024. Start your Free Trial

What is FibroBiologics Debt-to-Equity?

FibroBiologics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.36 Mil. FibroBiologics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.39 Mil. FibroBiologics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $1.25 Mil. FibroBiologics's debt to equity for the quarter that ended in Dec. 2023 was 1.39.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for FibroBiologics's Debt-to-Equity or its related term are showing as below:

FBLG' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.88   Med: -1.01   Max: 1.39
Current: 1.39

During the past 3 years, the highest Debt-to-Equity Ratio of FibroBiologics was 1.39. The lowest was -1.88. And the median was -1.01.

FBLG's Debt-to-Equity is ranked worse than
91.74% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs FBLG: 1.39

FibroBiologics Debt-to-Equity Historical Data

The historical data trend for FibroBiologics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroBiologics Debt-to-Equity Chart

FibroBiologics Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-Equity
-1.01 -1.88 1.39

FibroBiologics Quarterly Data
Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial N/A -1.88 0.17 0.17 1.39

Competitive Comparison of FibroBiologics's Debt-to-Equity

For the Biotechnology subindustry, FibroBiologics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

FibroBiologics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FibroBiologics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where FibroBiologics's Debt-to-Equity falls into.


FibroBiologics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

FibroBiologics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.362 + 1.385) / 1.253
=1.39

FibroBiologics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.362 + 1.385) / 1.253
=1.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

FibroBiologics  (NAS:FBLG) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

FibroBiologics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of FibroBiologics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

FibroBiologics (FibroBiologics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroBiologics Inc (NAS:FBLG) » Definitions » Debt-to-Equity
Comparable Companies
Traded in Other Exchanges
SG0:Germany
Address
455 E. Medical Center Boulevard, Suite 300, Houston, TX, USA, 77598
Website
https://www.fibrobiologics.com
FibroBiologics Inc is an early-stage, cell therapy company. Its primary focus is the initiation and progression of preclinical studies and clinical-stage FDA trials related to fibroblast treatments for Degenerative Disc Disease, Multiple Sclerosis, Cancer, Wound Healing, and other diseases.

FibroBiologics (FibroBiologics) Headlines

From GuruFocus

FibroBiologics Announces Three United States Patents for Fibroblast Technology

By PRNewswire • 02-12-2024

FibroBiologics Announces Three Japanese Patents on Fibroblast Technology

By PRNewswire • 02-12-2024